The estimated Net Worth of Christopher Towers is at least $376 dollars as of 24 February 2021. Christopher Towers owns over 800 units of GBS stock worth over $376 and over the last 4 years Christopher sold GBS stock worth over $0.
Christopher has made over 1 trades of the GBS stock since 2021, according to the Form 4 filled with the SEC. Most recently Christopher bought 800 units of GBS stock worth $5,472 on 24 February 2021.
The largest trade Christopher's ever made was buying 800 units of GBS stock on 24 February 2021 worth over $5,472. On average, Christopher trades about 400 units every 0 days since 2021. As of 24 February 2021 Christopher still owns at least 800 units of GBS stock.
You can see the complete history of Christopher Towers stock trades at the bottom of the page.
Christopher's mailing address filed with the SEC is C/O GBS INC., 142 WEST 57TH STREET, 11TH FLOOR, NEW YORK, NY, 10019.
Over the last 4 years, insiders at GBS have traded over $6,891,194 worth of GBS stock and bought 51,106 units worth $85,007 . The most active insiders traders include Science Biosensor Diagnosti..., Spiro Kevin Sakiris e Tom Parmakellis. On average, GBS executives and independent directors trade stock every 12 days with the average trade being worth of $51,467. The most recent stock trade was executed by Spiro Kevin Sakiris on 22 June 2022, trading 5,000 units of GBS stock currently worth $3,250.
GBS Inc. operates as a biosensor diagnostic technology company. It offers Saliva Glucose Biosensor that uses saliva to measure glucose non-invasively. The company also focuses on developing COV2 test, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumour markers, hormones, and nucleic acid diagnostic modalities. It has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
GBS executives and other stock owners filed with the SEC include: